Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:32 PM
Ignite Modification Date:
2025-12-24 @ 11:32 PM
NCT ID:
NCT02046356
Eligibility Criteria:
Inclusion Criteria:
* 18-70 years old
* The diameter of single tumor should be no more than 5cm, or multiple tumors(less than 3 loci) should be no more than 3cm. No large vascular invasion, no lymph nodes or extrahepatic metastases
* The Classification of patients' liver function is Child - Pugh A or B
* No serious coagulation dysfunction (prothrombin activity \< 40% or platelet count \< 30000 / mL).
* No refractory ascites.
* The patients can be treated with RFA in clinical
* Primary treatment by RFA should ablate the tumor(s) completely
* The patients are aware of their condition, the treatment of the HCC, and the risks associated with radiofrequency ablation therapy.
* The patients participant voluntarily and they will sign the informed consent before the radiofrequency ablation therapy.
Exclusion Criteria:
* The patients are from abroad, Hong Kong, Macao, Taiwan and other regions, who are impossible to be follow-up
* The patients who refuse to sign the informed consent
* Tumor emboli existed in main portal vein, ductus hepatics communis and(or) its primary branch, main hepatic vein and(or) inferior vena cava before operation
* Extrahepatic metastasis, lymph node metastasis
* The patients whom accept systemic chemotherapy, preoperative interventional therapy, and(or) other auxiliary treatment
* The patients with diabetes mellitus, heart disease and(or) other diseases can't tolerate radiofrequency ablation, or influence postoperative follow-up
* The existence of other type of malignant tumor before or accompanied by HCC
* Primary treatment by RFA do not ablate the tumor(s) completely
* Non-primary liver tumor, such as the liver metastatic carcinoma, cholangiocarcinoma, etc
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
70 Years
Study:
NCT02046356
Study Brief:
Protocol Section:
NCT02046356